H1 2026 Earnings
Financial report interval: 2025.12.30 - 2026.06.30
Overview: Can-Fite BioPharma(CANF) the Revenue is 202 K (--%), Beat estimate;the EBIT is -4.68 M (--%), Beat estimate;the EPS is -1.24 (--%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.00B--
0.00B--
+0.00B--%
EBITExceed expectations
-0.00B--
-0.01B--
+0.00B--%
EPSMiss expectations
-1.24--
-0.33--
-0.9100--%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf